Mitochondrial fission enhances IL ‐6‐induced metastatic potential in ovarian cancer via ERK1 /2 activation
Cancer Science · 2024
DOI: 10.1111/cas.16064 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cancer Science, 2024. Verfasst von Juwon Lee und 8 weiteren Autor:innen. Beteiligte Einrichtung: WCU Biomodulation, Department of Agricultural Biotechnology, Seoul National University, Seoul, Korea. Hauptthemen laut MEDLINE: Mitochondrial Dynamics, Ovarian Neoplasms, Interleukin-6, Dynamins. Die Arbeit wurde bisher 14-mal zitiert (Crossref) und nennt 79 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: 2022 cancer research support project, Korea Health Technology R&D Project.
Abstract (Originalsprache)
Ovarian cancer is a lethal gynecologic cancer mostly diagnosed in an advanced stage with an accumulation of ascites. Interleukin‐6 (IL‐6), a pro‐inflammatory cytokine is highly elevated in malignant ascites and plays a pleiotropic role in cancer progression. Mitochondria are dynamic organelles that undergo fission and fusion in response to external stimuli and dysregulation in their dynamics has been implicated in cancer progression and metastasis. Here, we investigate the effect of IL‐6 on mitochondrial dynamics in ovarian cancer cells (OVCs) and its impact on metastatic potential. Treatment with IL‐6 on ovarian cancer cell lines (SKOV3 and PA‐1) led to an elevation in the metastatic potential of OVCs. Interestingly, a positive association was observed between dynamin‐related protein 1 (Drp1), a regulator of mitochondrial fission, and IL‐6R in metastatic ovarian cancer tissues. Additionally, IL‐6 treatment on OVCs was linked to the activation of Drp1, with a notable increase in the ratio of the inhibitory form p‐Drp1(S637) to the active form p‐Drp1(S616), indicating enhanced mitochondrial fission. Moreover, IL‐6 treatment triggered the activation of ERK1/2, and inhibiting ERK1/2 mitigated IL‐6‐induced mitochondrial fission. Suppressing mitochondrial fission through siRNA transfection and a pharmacological inhibitor reduced the IL‐6‐induced migration and invasion of OVCs. This was further supported by 3D invasion assays using patient‐derived spheroids. Altogether, our study suggests the role of mitochondrial fission in the metastatic potential of OVCs induced by IL‐6. The inhibition of mitochondrial fission could be a potential therapeutic approach to suppress the metastasis of ovarian cancer.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- WCU Biomodulation, Department of Agricultural Biotechnology, Seoul National University, Seoul, Korea.
- Cancer Research Institute, College of Medicine, Seoul National University, Seoul, Korea.
- Department of Neurology and Neurological Sciences, Stanford University School of Medicine, Stanford, California, USA.
- Paul F. Glenn Laboratories for the Biology of Aging, Stanford University School of Medicine, Stanford, California, USA.
- Department of Medical Oncology, The First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, China.
- Department of Obstetrics and Gynecology, College of Medicine, Seoul National University, Seoul, Korea.
ORCID-Profile: Yong Sang Song
Förderung
- 2022 cancer research support project
- Korea Health Technology R&D Project
Zitieren
APA
Lee, J., Han, Y., Kim, S., Jo, H., Wang, W., Cho, U., Kim, S. I., Kim, B., & Song, Y. S. (2024). Mitochondrial fission enhances IL ‐6‐induced metastatic potential in ovarian cancer via ERK1 /2 activation. Cancer Science. https://doi.org/10.1111/cas.16064
Vancouver
Lee J, Han Y, Kim S, Jo H, Wang W, Cho U, et al. Mitochondrial fission enhances IL ‐6‐induced metastatic potential in ovarian cancer via ERK1 /2 activation. Cancer Science. 2024. doi:10.1111/cas.16064
BibTeX
@article{Lee2024,
author = {Lee, Juwon and Han, Youngjin and Kim, Soochi and Jo, HyunA and Wang, Wenyu and Cho, Untack and Kim, Se Ik and Kim, Boyun and Song, Yong Sang},
title = {Mitochondrial fission enhances IL ‐6‐induced metastatic potential in ovarian cancer via ERK1 /2 activation},
journal = {Cancer Science},
year = {2024},
doi = {10.1111/cas.16064}
}
EUVIMED